Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
Grant Opportunity Analysis
The National Cancer Institute, part of the National Institutes of Health, is seeking grant applications for early-stage innovative technology development for basic and clinical cancer research under the R61 mechanism, with clinical trials not allowed. The program supports proof-of-concept work to develop new molecular or cellular characterization technologies and improved biospecimen handling and quality control tools for cancer research, especially where the use case is cancer-relevant. Projects are expected to show novel technical capabilities, potential for transformative impact, and quantitative performance measures, and preliminary data are not required; applications centered on applying existing technologies to hypothesis-driven research are not responsive. NCI expects to commit $5.1 million for about 20 awards, with budgets capped at $150,000 per year for up to three years, applications due November 10, 2026, submitted electronically, and Kelly.crotty@nih.gov listed as the contact.
Eligible Applicants
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.